Microplastics and Cardiovascular Disease: Should Clinicians Be Paying Attention?
Pedro Rafael Vieira de Oliveira Salerno(Elmhurst Hospital Center), Sadeer Al‐Kindi(Houston Methodist), Ricardo J. Estrada-Mendizábal(Tecnológico de Monterrey), Sarju Ganatra(Lahey Hospital and Medical Center), Mohamed Bassiony(Elmhurst Hospital Center), Colin Carpenter(Elmhurst Hospital Center), Omar W Aboukhatwa(Mayo Clinic)
Cited by 1
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
|Cardio-Oncology|2019|184
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
|JACC Heart Failure|2023|100
Health position paper and redox perspectives - Disease burden by transportation noise
|Redox Biology|2023|79